Ramona Schlenker

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers.

First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers.

Journal: Journal for immunotherapy of cancer
Published: February 09, 2026

A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.

A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 21, 2025

Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Journal: Nature communications
Published: May 21, 2025

Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.

Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.

Journal: Blood advances
Published: April 21, 2025

Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.

Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.

Journal: Blood advances
Published: April 21, 2025

Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma.

Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma.

Journal: Med (New York, N.Y.)
Published: June 14, 2023

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.

Journal: Nature
Published: March 14, 2021

Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses.

Regulatory T Cells Shape the Differential Impact of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune Defenses.

Journal: International journal of radiation oncology, biology, physics
Published: February 19, 2021

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Journal: Science translational medicine
Published: October 08, 2018

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 13, 2018

Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.

Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.

Journal: Cancer research
Published: August 03, 2016

A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents.

A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents.

Journal: Cancer immunology, immunotherapy : CII
Published: October 16, 2015
Showing 1-12 of 13

Last Updated: 09/26/2026